Drug Trial Radar · NCT05176951
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Dec 22, 2022
Primary completion
Mar 14, 2024
Study completion Mar 14, 2024
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jan 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo
Conditions
- Pulmonary Hypertension
Interventions
Treprostinil PalmitilDrug
Oral inhalation using a capsule-based dry powder inhaler device.
PlaceboDrug
Oral inhalation using a capsule-based dry powder inhaler device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience Any Number of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 140
- Number of Participants Who Experience Any Number of Serious Adverse Events (SAEs)Time frame: Up to Day 140
- Change from Baseline in Saturation of Peripheral Capillary Oxygenation (SpO2) LevelsTime frame: Pre-, during, and post- 6-minute walk test (6MWT) at Baseline, Week 5, Week 10, and Week 16
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
ARG008
Buenos Aires, Argentina
ARG003
Barracas, Ciudad Autónoma de BuenosAires, Argentina
ARG001
Rosario, Santa Fe Province, Argentina
AUS003
Camperdown, New South Wales, Australia
AUS005
Macquarie Park, New South Wales, Australia
BEL002
Liège, Belgium
GER002
Berlin, Germany
GER012
Berlin, Germany
GER004
Munich, Germany
GER006
Heidelberg, Baden-Wurttemberg, Germany
GER010
Giessen, Hesse, Germany
GER003
Essen, North Rhine-Westphalia, Germany
GER001
Dresden, Saxony, Germany
ITA003
Naples, Campania, Italy
ITA004
Milan, Lombardy, Italy
ITA002
Monza, Lombardy, Italy
ITA001
Palermo, Sicily, Italy
ESP010
Barcelona, Spain
ESP005
Barcelona, Spain
ESP006
Las Palmas de Gran Canaria, Spain
ESP009
Santiago de Compostela, Spain
ESP003
Palma de Mallorca, Balearic Islands, Spain
ESP007
Oviedo, Principality of Asturias, Spain
GBR003
Glasgow, Lanarkshire, United Kingdom
GBR001
Sheffield, Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.